Heterocyclic compounds used as FGFR inhibitors
AssigneeNanjing InnoCare Pharma Tech Co., Ltd.
InventorsNorman Xianglong Kong, Chao Zhou, Zhixiang Zheng
Life of this patent
Estimating the term…
Abstract
The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph, isomer or stable isotopic derivative thereof. The present invention further relates to use of the compound for the treatment or prevention of related diseases which are FGFR-mediated such as cancer, and a method for applying the compound to treat said diseases.
Claims8
A compound of Formula V or a pharmaceutically acceptable salt thereof:
- wherein RZ1 is selected from the group consisting of, halogen, and C1-C4 alkyl optionally substituted with hydroxyl, or
- RZ1 is
- R7 is hydrogen or C1-C4 alkyl;
- R11 is selected from the group consisting of NR2R3, halogen, and —O—(C1-C8 alkylene)-ORa;
- R2, and R3 are independently C1-C8 alkyl, wherein the alkyl is optional substituted by —ORb;
- and
- Ra and Rb are independently H or C1-C8 alkyl.
A compound of Formula V or a pharmaceutically acceptable salt thereof,
- wherein Rz1 is
- R7 is hydrogen or C1-C4 alkyl;
- R11 is —O—(C1-C8 alkylene)-ORa, and
- Ra is H or C1-C8 alkyl.
A compound of Formula V′ or a pharmaceutically acceptable salt thereof:
- wherein RZ1 is
- R7 is hydrogen or C1-C4 alkyl;
- R11 is selected from the group consisting of NR2R3, halogen, C1-C3 alkoxy, and OR4;
- R2, R3 and R4 are independently H and C1-C8 alkyl, wherein the alkyl is optional substituted by —OR5;
- and
- R5 is H or C1-C8 alkyl.
A compound having the following formula, or the pharmaceutically acceptable salt thereof:
Dependencies are inferred from the claim text.